As 2026 begins, a slate of high-stakes clinical readouts—from a pivotal study of Novartis’ cardiovascular candidate ...

Axsome Therapeutics recently reported that the FDA accepted its supplemental application and granted priority review for AXS-05 to treat agitation in Alzheimer’s disease, while also confirming that ...

US FDA accepts Axsome Therapeutics’ supplemental New Drug Application for AXS-05 to treat Alzheimer’s disease agitation: New York Saturday, January 3, 2026, 12:00 Hrs [IST] Ax ...

Shanghai Fosun Pharmaceutical Group Co. will acquire a controlling stake in a Chinese company that developed the country’s ...

Most of the time, you assume your brain is either “on” or “off,” awake or asleep. A new study shows something far more ...

In early December, the 2025 updates of China’s NRDL were finalised with a total of 114 drugs, including Western drugs and ...

Researchers are slowly tossing much of what we've been told for many years about Alzheimer's disease out the window — and replacing what has been a very dreary tale with new findings.

Memories of past trauma could soon be 'dialed down' in the brain so they no longer haunt us. The same techniques could ...

When Patty Norman first noticed concerns about her memory, she and her husband, Tommy Norman, faced uncertainty about what ...

From AI-powered drug discovery to regenerative therapies and next-generation neurology tools, Mayo Clinic researchers made significant strides in 2025 toward predicting, preventing and treating some o ...

Alzheimer’s disease blood test developer Quanterix put forward new clinical data from its Simoa assay, which it described as ...

Alzheimer's disease affects the brain in tragic and seemingly irreversible ways, but a new study gives hope that its ...